arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

DBV Technologies S.A.

DBVT
$13.52 ▼ -0.16 (-1.17%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

DBV Technologies S.A. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.9B
Dividend Yield
Revenue Growth -52.2%
Op. Margin None
ROIC -31.7%
FCF / Share $-0.12
Trailing P/E
Price / Book 36.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$700.00K
↓ -52.2%
Net Income Profit after all expenses
$-47.60M
↓ -75.8%
Operating Margin Operating profit as % of sales
-134.3%
↑ +70.8%
FCF / Share Free cash flow per share
$-0.12
↓ -5.8%
Long-Term Debt Long-term obligations
$510.00K
↓ -59.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 28 quarters